Fletikumab

Fletikumab

Monoclonal antibody
Type	?
Target	IL20
Clinical data
Other names	NNC0109-0012
ATC code	none
Identifiers
CAS Number	1357158-22-5
ChemSpider	none
UNII	82WG3POL9W
KEGG	D11756
ChEMBL	ChEMBL3301580
Chemical and physical data
Formula	C6494H10000N1728O2050S44
Molar mass	146492.12 g·mol^−1

Fletikumab (NNC0109-0012) (INN^[1]) is a monoclonal antibody designed for the treatment of rheumatoid arthritis^[2] that targets IL-20.^[3]

This drug was being developed by Novo Nordisk A/S until Novo ceased work in inflammation.

References

1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
2. Statement On A Nonproprietary Name Adopted By The USAN Council - Fletikumab, American Medical Association.
3. Kragstrup TW, Andersen T, Heftdal LD, Hvid M, Gerwien J, Sivakumar P, Taylor PC, Senolt L, Deleuran B (2018). "The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis". Frontiers in Immunology. 9: 2226. doi:10.3389/fimmu.2018.02226. PMC 6167463. PMID 30319661.